<bill session="110" type="sc" number="88" updated="2022-02-03T05:09:47Z">
  <state datetime="2008-06-10">REFERRED</state>
  <status>
    <introduced datetime="2008-06-10"/>
  </status>
  <introduced datetime="2008-06-10"/>
  <titles>
    <title type="display">A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.</title>
    <title type="official" as="introduced">A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.</title>
  </titles>
  <sponsor bioguide_id="C001056"/>
  <cosponsors>
    <cosponsor bioguide_id="B001066" joined="2008-06-10"/>
    <cosponsor bioguide_id="I000024" joined="2008-06-17"/>
  </cosponsors>
  <actions>
    <action datetime="2008-06-10">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2008-06-10" state="REFERRED">
      <text>Referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <reference ref="CR S5455-5456" label="text of measure as introduced"/>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="110" type="hc" number="342" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug approvals"/>
    <term name="Estrogen"/>
    <term name="Physicians"/>
    <term name="Women"/>
    <term name="Women's health"/>
  </subjects>
  <amendments/>
  <summary date="2008-07-15T17:51:02Z" status="Introduced in Senate">Calls for the Food and Drug Administration (FDA) to reverse its policy that aims to eliminate patient access to compounded medications containing estriol prescribed by physicians unless it holds a public comment period on the issue and can document evidence of adverse events and other safety issues to justify such policy.</summary>
</bill>
